Artificial intelligence (AI) software developer RapidAI has received clearance from the U.S. Food and Drug Administration (FDA) for its software that detects suspected large-vessel occlusions (LVO).
Rapid LVO identifies suspected LVOs using vessel tracking and assessment of brain regions with reduced blood vessel density. It analyzes images in as few as three minutes and has a sensitivity of 97% and specificity of 96%, according to the company.
